Under construction – not a live service
Sign in
Taking peoplePhase 3

Screening people with Alzheimer's disease for possible future studies

Checks whether adults with Alzheimer's disease may qualify for later research studies.

Plain-language title generated from the registry record
Registry title: Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Key facts

Where
?ód?, ?ory, B?dzin, Bia?ystok, Bydgoszcz, Gda?sk, Gdansk, Katowice, Krakow, Lublin, Późna, Rzeszów, Ścinawa, Sopot, Warsaw, Wroc?aw, and Zabrze, PolandSee the 21 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 90 years old?

Source: NCT07177352, who can take part

Where in Poland

  • Uniwersytet Medyczny w Lodzi?ód?, PolandNo longer taking part
  • ProNeuro Centrum Medyczne?ory, PolandNo longer taking part
  • Syberka-ClinHouse Sp. z o.o.B?dzin, PolandNo longer taking part
  • Podlaskie Centrum PsychogeriatriiBia?ystok, PolandNo longer taking part
  • Centrum Medyczne Neuromed Sp. z.o.o.Bydgoszcz, PolandNo longer taking part
  • Centrum Badan Klinicznych PI-House sp. z o.o.Gda?sk, PolandNo longer taking part
  • Uniwersyteckie Centrum Kliniczne;Klinika Neurologii Doros?ychGdansk, PolandNo longer taking part
  • Neuro-Care Gabriela KlodowskaKatowice, PolandNo longer taking part
  • Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii KKrakow, PolandNo longer taking part
  • Szpital Uniwersytecki w KrakowieKrakow, PolandNo longer taking part
  • Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.Lublin, PolandNo longer taking part
  • Clinical Research Center Sp. z o.o. MEDIC-R Spó?ka KomandytowaPóźna, PolandNo longer taking part
  • Centrum Medyczne MedykRzeszów, PolandNo longer taking part
  • Nmedis sp. z o.o.Rzeszów, PolandNo longer taking part
  • O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawieŚcinawa, PolandNo longer taking part
  • Senior Sp. Z O.O. Poradnia PsychogeriatrycznaSopot, PolandNo longer taking part
  • Centrum Leczenia Zaburzen PamieciWarsaw, PolandNo longer taking part
  • Centrum Medyczne NeuroProtectWarsaw, PolandNo longer taking part
  • ETG Neuroscience Sp. z o.o.Warsaw, PolandNo longer taking part
  • NZOZ WCAWroc?aw, PolandNo longer taking part
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa SzyszkoSUM w KatowicachZabrze, PolandNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hoffmann-La Roche
Trial code
NCT07177352
Record updated
19 October 2026
Original description
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.Read full original descriptionShow less

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Inclusion: Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges); Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study.

Exclusion: For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary; Dependency in basic activities of daily living (bADLs) due to cognitive impairment; Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted); Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD; History of severe, clinically significant central nervous system trauma; Any serious medical condition that precludes a participant's safe participation and completion of a clinical study.

ClinicalTrials.gov NCT07177352